Inhibition of P42 MAPK Using A Nonviral Vector-Delivered siRNA Potentiates The Anti-Tumor Effect of Metformin in Prostate Cancer Cells

Abstract

Blockade of the MAPK pathway using a dendrimer-vehiculized siRNA to block the MAPK signaling pathway in prostate cancer cells can potentiate the anti-tumoral activity of anticancer drugs, indicating that the combination of siRNA-mediated blockade of survival signals plus anti-tumoral therapy might be a useful approach for cancer therapy.